Dr. Xingli Wang

And for the HLX22, we also adopt the similar strategy as when we did the PD-1 drug.

And we started with gastric cancer.

The metastatic gastric cancer is the first indication to develop rather than breast cancer.

But breast cancer currently is also on phase two.

And this gastric cancer, what we have shown by giving patients together with trastuzumab, from phase two results, it really has dramatic outcome.

And if you talk about the target product profile, it has at least in the HR somewhere around 0.6 in the PFS and for the OS is somewhere around 0.7.

I mean, obviously when you come to the phase three data hasn't come out, hasn't complete yet, but it's going to be 2027 and it's currently conducted in US led by the PI from MD Anderson.

and this one again it by phase two data showed really far better profile than you through the other just HER2 alone and obviously when we do also looking at the breast cancer currently on phase two as I mentioned it's also going to be like you do together the our current belief is a dual the HER2 inhibitor

by working together or giving patients together with trastuzumab, you will have a much better outcome.

I would say this again reflected when we choose which indication to develop first,

As a clinical development strategy, this is another winning example.

And I remember when I was in the Maritas, we talked about the capabilities of a clinical development.

One of the keys is how do you design your clinical development proposal, the plan, as a strategy, which indications start first, which often determines whether you're able to secure enough resource to continue the development of the asset.

So this, again, reflecting that.

I mean, obviously, when we come to ADC, ADC is probably currently the most popular ones.

And the shortcomings, I mean, the shortfall of ADC is also obvious because of the potential toxicity.

I think with this HER2 together with N-HER2, with ADC combined,

you probably would be able to have a less toxic effect by reducing the dose a bit of the ADC because of this particular effect.

And I do see the potential combination, but need to be titrated well of the dosing in order to reduce the ADC side effect and at the same time improve or materially improve the efficacy together.

No, they're quite different, yeah.